STOCKS TELEGRAPH

Tag: Creative Medical Technology

  • 3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    The biotechnology industry remains characterized by a steady flow of research-driven updates, including trial expansions, protocol refinements, and regulatory communications. Each of these elements can contribute to shifting expectations around a therapy’s future viability. As companies move deeper into late-stage studies, the market increasingly weighs the probability of success against the remaining development risk.

    Creative Medical Technology Holdings Inc (CELZ)

    Creative Medical Technology Holdings Inc (NASDAQ: CELZ) started the day on May 08, 2026, with a 0.87% price increase to $2.31. During the day, the stock rose to $2.38 and sank to $2.10. Taking a long-term approach, CELZ posted a 52-week range of $1.50-$6.25.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 66.83%. Meanwhile, its Annual Earnings per share during the time was 66.83%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 37.70%. This publicly-traded company’s shares outstanding now amount to $3.70 million, simultaneously with a float of $3.66 million. The organization now has a market capitalization of $8.54 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to expand its cardiovascular development platform by targeting inflammatory heart diseases with limited treatment options. Beyond recurrent pericarditis, the company is building clinical evidence in acute myocarditis, a serious condition that can lead to long-term cardiac complications and currently lacks targeted therapies.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company maintains a market capitalization of $147.418M and a beta of 0.43, reflecting relatively stable trading characteristics for a clinical-stage biotech company. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 highlights substantial upside potential tied to future clinical execution.

    Clinical Expansion: ARCHER Study

    Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in patients with acute myocarditis, a condition involving inflammation of the heart muscle that can progress to heart failure or arrhythmias. The study demonstrated reductions in cardiac inflammation along with structural improvements, including decreases in left ventricular mass, an important marker associated with cardiac remodeling and recovery.

    Scientific and Strategic Relevance

    The recent announcement that CardiolRx™ Phase II pericarditis results will be published in the Journal of the American Heart Association adds broader scientific credibility to the company’s anti-inflammatory platform. Positive findings across multiple inflammatory cardiac conditions may strengthen confidence in the therapeutic potential of CardiolRx™ beyond a single indication.

    Outlook

    As Cardiol advances development across multiple cardiovascular diseases, successful clinical validation in myocarditis could meaningfully expand the company’s long-term commercial opportunity and reinforce its broader pipeline strategy.

    Nexalin Technology Inc (NXL)

    As of May 08, 2026, Nexalin Technology Inc (NASDAQ: NXL) got off with the flyer as it spiked 2.44% to $0.35. During the day, the stock rose to $0.36 and sank to $0.35. Taking a more long-term approach, NXL posted a 52-week range of $0.33-$2.00.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -1.42%. Meanwhile, its Annual Earnings per share during the time were -1.42%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 30.00%. This publicly-traded company’s shares outstanding now amount to $20.58 million, simultaneously with a float of $16.33 million. The organization now has a market capitalization of $7.25 million.

  • Creative Medical (CELZ) Shares Continued The Rally In After-Hour Trading

    Creative Medical (CELZ) Shares Continued The Rally In After-Hour Trading

    Investor excitement following encouraging clinical trial findings was reflected in the substantial increase in the stock price of Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) on Thursday. During regular trading, CELZ shares rose 11.14%, concluding at $4.59. After-hours trading saw an additional 8.93% increase, hitting $5.00.

    Promising Results for Type 2 Diabetes Therapy

    Creative Medical Technology released one-year follow-up data from its AlloStem (CELZ-201) pilot study, targeting late-stage Type 2 Diabetes patients. CELZ-201 is an allogenic, ready-to-use cell therapy designed to reduce insulin dependency and stabilize blood sugar levels. The study demonstrated an 80% overall efficacy rate in achieving these outcomes, with no reported serious adverse effects.

    The trial involved 20 participants, with 10 receiving the CELZ-201 infusion and 10 undergoing optimized medical therapy. Results confirmed the safety and effectiveness of the treatment, which utilizes the same infusion method currently being tested in the company’s FDA-approved Type 1 Diabetes clinical trial. The lack of safety issues emphasizes even more how promising CELZ-201 is as a ground-breaking diabetic therapy.

    Resolving a Pervasive Health Issue

    Type 2 diabetes, the seventh greatest cause of death in the US, affects 90–95% of the 38 million Americans and is a serious public health risk. More than 80% of the 96 million people who have prediabetes are not aware that they have the disease. Even though early-stage management involves lifestyle changes and oral medications, many patients eventually require insulin treatment as the diabetes worsens. 

    Future Growth and Innovation

    In light of these encouraging outcomes, Creative Medical Technology plans to investigate other therapeutic uses and expedite the development of AlloStem or CELZ-201 for advanced Type 2 Diabetes. The company’s diverse pipeline, which includes CELZ-201 for Type 1 diabetes in its early stages and CELZ-101 for brittle Type 1 diabetes, demonstrates its dedication to developing cutting-edge therapies that might fundamentally alter the way diabetes is managed.

  • Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Presently in the current trading session, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is experiencing a notable surge, marking a 22.80% increase to $5.00 as per the latest update. This uptrend in CELZ stock correlates with the regulatory clearance obtained for a novel pharmaceutical product by the company.

    The U.S. Food and Drug Administration (FDA) has designated CELZ-101, often referred to as ImmCelz, as an orphan drug as publicly disclosed by Creative Medical Technology (CELZ). This innovative therapy aims to shield recipients of pancreatic islet cell transplants against allograft rejection.

    For people with fragile Type 1 diabetes, a condition characterized by erratic fluctuations in blood glucose levels, it is a significant breakthrough. CELZ-101, alternatively termed as Supercharged Treg Biologic Immunotherapy (ImmCelz), epitomizes a cutting-edge paradigm in personalized healthcare, leveraging the patient’s own regulatory T cells (Tregs) to counter autoimmune and alloimmune responses that may jeopardize insulin-producing cells.

    This groundbreaking therapy is rooted in a proprietary methodology not only amplifying Tregs but also augmenting their efficacy, promising a viable avenue to diminish the necessity for lifelong immunosuppressive measures. The conferment of Orphan Drug Designation by the FDA for CELZ-101 underscores the unwavering dedication of the company towards pioneering therapeutic modalities.

    This pivotal achievement catapults the endeavor closer towards offering a sustainable resolution for individuals contending with the persistent challenges of brittle Type 1 diabetes, hallmarked by erratic glycemic fluctuations. It is in consonance with CELZ’s overarching mission to enhance the quality of life for patients through the vanguard of regenerative medicine.

    The advancement of CELZ-101 marks a significant stride in the domain of cell-based immunotherapy, addressing the imperative requirement for more efficacious interventions in brittle Type 1 diabetes by striving for operational tolerance in islet cell transplantation, potentially liberating patients from the onus of lifelong immunosuppression.

    This heralds the debut of the first orphan-designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes. The Orphan Drug Designation accorded by the FDA accentuates the potential of CELZ-101 in fulfilling a substantial unmet need in averting allograft rejection during pancreatic islet cell transplantation, which recently garnered FDA approval.

    This designation confers numerous consequential advantages to bolster the progression of the therapy including tax incentives, exemptions from user fees, and the prospect of market exclusivity post-approval.